Effects of dienogest treatment on endometrioma-related clinical symptoms and endometrioma size: retrospective cohort study

Ufuk Atlıhan, Onur Yavuz, Can Ata, Hüseyin Aytuğ Avşar, Selçuk Erkılınç
In: Frontiers in Medicine · 2025 · vol. 12 , pp. 1581661 · doi:10.3389/fmed.2025.1581661 · PMID:40375929 · W4410015496
article OA: gold CC0 ⤵ 2 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Dienogest treatment significantly reduced endometrioma size and pain scores within six months, with maximum efficacy observed in patients treated for over one year.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Background To evaluate the efficacy and long-term safety of treatment with dienogest in patients with endometrioma. Methods Patients with endometrioma-related chronic pelvic pain were included in this retrospective study from March 2018 to March 2023. Enrolled patients received 2 mg of dienogest once daily. Data from 180 patients were analyzed. Group 2 ( n = 104, 57.8%), comprising patients undergoing long-term therapy (>12 months), was compared with group 1 ( n = 76, 42.2%), consisting of patients undergoing short-term therapy (<2 months), regarding their response to changes in endometrioma size and visual analog scale (VAS) scores. Statistical analysis was performed using the SPSS version 26.0 software. Non-normally distributed parameters were analyzed using the Mann–Whitney U test. In the evaluation of the data, apart from identifying statistical methods, the t-test was used in comparison of paired groups, and the matched t-test was used in the determination of changes before and after treatment. The Chi-square test and Fisher’s precision test were used in the analysis of categorical data. Categorical variables are presents as percentages, and quantitative variables are summarized as mean (95% confidence intervals) and median (minimum-maximum). p -values of <0.05 were considered statistically significant. Results Findings at T0 (baseline) and T1 (sixth month) visits, in which the entire study cohort could be included, were compared. Then, patients who continued treatment at visits every 6 months after T1 (>12 months) were compared one by one with the findings at T0. The reduced libido was 4.3 times higher in the long-term group, but the weight gain was higher in the short-term group. Analysis within all patients and individual groups (short term vs. long term) showed a significant decrease in endometrioma size and VAS scores between T0 and T1 visit findings. Similarly, the findings of T2 and each subsequent visit of the patients in the long-term group were compared with the initial findings and a significant reduction in endometrioma size and VAS scores was observed. Conclusion Although the effectiveness of dienogest treatment for endometrioma seems to begin in the sixth month, its effectiveness maximizes in patients whose treatment duration is over 1 year.

My notes (saved in your browser only)

Outcome instruments

VAS-pain

Condition tags

endometriomachronic_pelvic_pain

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (36)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK